about
Early use of inhaled corticosteroids in the emergency department treatment of acute asthmaEarly use of inhaled corticosteroids in the emergency department treatment of acute asthmaDifferential cytokine profiles upon comparing selective versus classic glucocorticoid receptor modulation in human peripheral blood mononuclear cells and inferior turbinate tissueA comparison of the clinical efficacy and safety of intranasal fluticasone propionate and antihistamines in the treatment of rhinitis.Topical corticosteroids in allergic rhinitis; effects on nasal inflammatory cells and nasal mucosa.Clinical utility and patient adherence with ebastine for allergic rhinitis.Role of Bcr1-activated genes Hwp1 and Hyr1 in Candida albicans oral mucosal biofilms and neutrophil evasionSafety of inhaled corticosteroids in children.Pregnancy rhinitis and rhinitis medicamentosa.Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposureActual therapeutic management of allergic and hyperreactive nasal disordersComparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials.Glucocorticoid receptors in human airways.Using corticosteroids during pregnancy. Are topical, inhaled, or systemic agents associated with risk?Impact of allergic rhinitis in school going children.Emerging anti-inflammatory agents for allergic rhinitis.Topical glucocorticosteroids in rhinitis: clinical aspects.Novel therapeutic interventions for allergic rhinitis.New treatment options in allergic rhinitis: patient considerations and the role of ciclesonideTolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review.Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma.Allergic rhinitis in women.Investigational drugs for allergic rhinitis.Effect of ciclesonide on allergen challenge in subjects with bronchial asthma.Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis.Nasal corticosteroids, first choice in moderate to severe allergic rhinitis. What prevents general practitioners from using them?Perennial rhinitis in the under 4s: a difficult problem to treat safely and effectively? A comparison of intranasal fluticasone propionate and ketotifen in the treatment of 2-4-year-old children with perennial rhinitis.Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults.The relationship of depression in asthma-chronic obstructive pulmonary disease overlap syndrome.Overview of novel therapeutic targets for asthma and chronic obstructive pulmonary disease.Oral health: Asthma and oral candidiasis.Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.Can intranasal corticosteroids cause migraine-like headache?
P2860
Q24202511-8B19891B-2386-4BE9-954C-8ED15B473FB3Q24247958-69C20BDC-11E1-431E-B075-D5911E28750CQ28546223-BB4430C3-8386-4210-A4B4-E1AE81F6CBC1Q33993551-CEC630FE-1B34-4186-A5D3-B54C2147881FQ34255293-45D2244F-1BA7-4E1A-B57B-B6027EC0B7BAQ34413618-4E4366F6-F40D-4AE5-A9B9-0B8AEC7CC265Q34520316-B95082A9-36FD-4201-B4E7-A3064E34D5DCQ34523194-10FDE2A7-56FE-4053-8201-AC523BABDFD4Q35059910-F4EC4E1A-6C83-40B7-90A6-3923629FFCE2Q35113146-E8C720F4-2B80-4C30-BF0B-3FEA0E319843Q35427205-E0C0F0B1-0078-4694-B61A-F078E8F84C59Q35627751-7D65C418-A786-4F5D-864E-528EEFB810AAQ35881911-6A1F7384-E7F8-4922-B8C5-51230B02680AQ35904649-E309D050-CD4D-42C3-8012-4C4574E0A282Q35937141-D8141068-1B38-47F3-88B3-CAEB0102A503Q36302823-31D6BAE1-FF2E-4EFA-B7DE-0F645B573A0BQ36573081-0CD3B406-D0B8-4992-9E43-246B9202928BQ36654345-F7C4A32A-211E-49DB-87DC-2FBF50509B9EQ36823610-E426717C-5384-4638-BA26-68B9C724AE2BQ36892408-1A2C9625-D911-4110-B93B-57E8748C3D31Q37436410-33D84A59-9788-4C48-AF14-B0FDFBEC17A2Q37608446-BAB44911-132A-4805-9A44-0A99911CAA96Q37650382-2329B785-7E07-4B4A-B72A-88B761759989Q44373597-D49ED501-8B94-48D1-9881-19473AB01715Q44474641-E470BBBD-4C10-4684-9DE3-57D17BBF0BA2Q44512143-E8317458-C189-43A6-8502-3C31EDF45040Q44946504-BD759D47-F4EE-437B-A19F-8DFDB4517A88Q46486322-D260C428-CB74-41AC-9D33-35C2EC0D3CF2Q47159244-6EC6C558-D230-4485-9136-475E5FBA3ECFQ47772639-1BF1DEAE-7D9F-4B27-8D8F-486271F284B8Q50082244-C3C6683D-C6E5-4B88-B38B-0B219E2A4684Q50940313-D8B43AB7-68C2-4E99-8B30-86F57E61EC95Q53200781-DB81000E-A655-42A3-9887-542B2C919A06
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Inhaled and nasal corticosteroids: safety aspects.
@ast
Inhaled and nasal corticosteroids: safety aspects.
@en
type
label
Inhaled and nasal corticosteroids: safety aspects.
@ast
Inhaled and nasal corticosteroids: safety aspects.
@en
prefLabel
Inhaled and nasal corticosteroids: safety aspects.
@ast
Inhaled and nasal corticosteroids: safety aspects.
@en
P2093
P2860
P1433
P1476
Inhaled and nasal corticosteroids: safety aspects.
@en
P2093
Canonica GW
Kontou-Fili K
Malling HJ
Passalacqua G
Van Cauwenberge P
P2860
P356
10.1034/J.1398-9995.2000.00370.X
P577
2000-01-01T00:00:00Z